Other Events ·
Purple Biotech Ltd. filed a Form 6-K on August 10, 2026, to furnish its updated corporate presentation dated August 2026
PPBTPurple Biotech Ltd.
Purple Biotech Ltd. filed a Form 6-K on August 10, 2026, to furnish its updated corporate presentation dated August 2026. The filing highlights the company's financial position as of June 30, 2026, reporting $6.1 million in cash and a projected runway extending to mid-2027. It outlines the development pipeline for lead candidate IM1240, a tri-specific antibody expected to enter clinical trials in 2027, alongside preclinical data for other programs including CM24 and NT219. The presentation details safety and efficacy results from IND-enabling studies and Phase 2 proof-of-concept data for CM24 in pancreatic cancer. Purple Biotech Ltd. operates in the biotechnology industry, focusing on developing immuno-oncology therapies.